Novartis Adds To NASH Pipeline By Licensing Pliant’s Integrin Inhibitor

Deal for preclinical asset adds an anti-fibrotic mechanism to Novartis’ NASH program. Pliant produced preclinical data showing strong anti-fibrotic effect.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.
Novartis has made several deals to add to its NASH pipeline

A company paying $80m up front to license a preclinical asset can turn heads, but Novartis AG is committing that much for Pliant Therapeutics Inc.’s integrin inhibitor PLN-1474 for two reasons – it adds a drug with an anti-fibrotic mechanism to its portfolio of non-alcoholic steatohepatitis (NASH) candidates, and the drug’s preclinical development included head-to-head testing with other NASH candidates in human liver tissue from transplant patients.

South San Francisco-based Pliant announced before the markets opened on 23 October that it will get $80m up front –...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.